Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
Antioxidants & Redox Signaling|February 23, 2010
Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductaseJennifer D Tibodeau, Crescent R Isham, Keith C Bible
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Systemic therapeutic approaches to advanced thyroid cancersMichael E Menefee, Robert C Smallridge, Keith C Bible
Journal of Bone Oncology|March 11, 2020
Bone metastases in thyroid cancerNicole M Iñiguez-Ariza, Keith C Bible, Bart L Clarke
The Lancet. Diabetes & Endocrinology|June 6, 2014
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targetsChristine Spitzweg, Keith C Bible, Lorenz C Hofbauer, et al.
Journal for Immunotherapy of Cancer|August 2, 2020
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinomaSara Bedrose, Kevin Charles Miller, Lina Altameemi, et al.
Journal for Immunotherapy of Cancer|July 2, 2014
Strategies for improving the reporting of human immunophenotypes by flow cytometryMichael P Gustafson, Yi Lin, Mabel Ryder, et al.
Molecular Cancer Therapeutics|January 25, 2006
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergyYean Kit Lee, Crescent R Isham, Scott H Kaufman, et al.
Endocrinology and Metabolism Clinics of North America|February 6, 2019
Diagnosis and Management of Anaplastic Thyroid CancerAshish V Chintakuntlawar, Robert L Foote, Jan L Kasperbauer, et al.
Thyroid : Official Journal of the American Thyroid Association|May 5, 2017
Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid CancerNicole M Iñiguez-Ariza, Mabel M Ryder, Crystal R Hilger, et al.
Endocrine-Related Cancer|March 11, 2014
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionMabel Ryder, Margaret Callahan, Michael A Postow, et al.
Pageof 10